Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422471 · ClinicalTrials.gov registry record · NA
Hypoglycemia and Autonomic Nervous System Function- B2
A NA study of Type 2 Diabetes and Hypoglycemia, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03422471: Completed NA study of Type 2 Diabetes and Hypoglycemia, sponsored by Brigham and Women's Hospital.
NCT03422471 is a NA study of Type 2 Diabetes and Hypoglycemia that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 14 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03422471, a NA study of Type 2 Diabetes and Hypoglycemia, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
We will study the effect of hypoglycemia (low blood sugar) on baroreflex sensitivity in participants with well controlled type 2 diabetes.
Primary Outcome
Change in baroreflex sensitivity between the first assessment (pre-AM clamp on Day 1) and the final assessment (AM of Day 2, about 16 hours after the PM clamp)
Conditions Studied
Interventions
- OTHER Hyperinsulinemic Hypoglycemic Clamp
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2025-11-25 |
| Phase | NA |
What the finished NCT03422471 record still lists
NCT03422471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Hyperinsulinemic Hypoglycemic Clamp is the first listed.
NCT03422471 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03422471 about?
NCT03422471 is a clinical study titled "Hypoglycemia and Autonomic Nervous System Function- B2". We will study the effect of hypoglycemia (low blood sugar) on baroreflex sensitivity in participants with well controlled type 2 diabetes.
What is the current status of trial NCT03422471?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2017-09-25. Estimated completion is 2025-11-25.
What conditions does trial NCT03422471 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Hypoglycemia.
What interventions are being tested in trial NCT03422471?
The interventions under investigation include: Hyperinsulinemic Hypoglycemic Clamp (OTHER).
Who is sponsoring clinical trial NCT03422471?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03422471 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03422471's enrollment target sits among peer trials
14 312th of 327 higher than 15 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy